Clinical trial reports six and a half month longer survival in patients who were treated with new treatment for ALS.
Amyotrophic lateral sclerosis or ALS is a progressive nervous system disorder that affects nerve cells in the brain and spinal cord, causing muscle weakness and loss of control. It is also known as Lou Gehrig’s disease after the baseball player was diagnosed with it. ALS usually begins with muscle twitching and weakness in a limb or slurred speech. Eventually, the disease affects control of the muscles needed to move, speak, eat, and breathe.
A clinical trial – called the CENTAUR trial – has reported up to six and a half month longer survival in patients who were treated with the experimental treatment, AMX0035.
The investigators, led by Sabrina Paganoni, MD, Ph.D., of the Healey & AMG Center for ALS at Massachusetts General Hospital, noted that these data, combined with the study’s previously reported results, suggest that the therapy provides patients both functional and survival benefits.
These new findings are significant, as there are only two available ALS treatments, riluzole and edaravone. As of yet, only riluzole had been shown to prolong survival. The effects of edaravone on survival are unknown.
In the randomized trial, included individuals were randomized in two-to-one fashion to AMX0035 (3-g PB and 1-g TURSO per sachet) or matching placebo, administered twice daily by mouth or feeding tube for a planned duration of six months. Additionally, patients eligible for the open-label extension (OLE) were given the option to enroll in an OLE and receive the active drug for around thirty months. In total, ninety-two percent of the study population enrolled. The team evaluated the long-term safety and efficacy of the new ALS treatment during the follow-up.
The analysis included 135 patients randomized in the trial, with median overall survival being 25 months for those treated with AMX0035 compared with a median survival of 18.5 months in the placebo group, equating to a forty-four percent lower risk of death.
Nearly three-year survival analysis incorporated all participants who enrolled in CENTAUR, whether they continued long-term treatment with AMX0035 in the open-label extension or not. The team found that AMX0035 treatment resulted in a 6.5-month longer median survival as compared to a placebo. These results support that AMX0035 has both functional and long-term survival benefits.
Reference: Paganoni S., Hendrix S., Dickson SP., Knowlton N., Macklin EA., Berry JD., Cudkowicz M.E. Long-Term Survival of Participants in the CENTAUR Trail of Sodium Phenylbutyrate-Taurursodiol in ALS. Muscle Nerve. 2020 Oct 16. doi: 10.1002/mus.27091.
Related Post
Feb
How a Growing Crisis of Loneliness Is Affecting Americans Health
America has another scourge. It can't be dealt with utilizing conventional treatments despite the fact that it has crippling and, surprisingly, dangerous outcomes. The issue leaking in at the sides of our networks is depression and U.S. Top health spokesperson Dr..
Read MoreFeb
The Cost of Loneliness in Retirement
While we frequently stress over saving enough for retirement, the expense of depression is ascending as an equivalent danger to a blissful, solid retirement. Yet, there are steps you can take now to fabricate your social capital. Depression and social confinement.
Read MoreFeb
10 Ways to Reduce Your Risk of Colorectal Cancer
Colorectal malignant growth is the subsequent driving reason for disease related passings, influencing millions around the world. As per the American Malignant growth Society, around 1 out of 20 individuals will be determined to have colorectal disease during their lifetime..
Read MoreFeb
10 Signs You May Need Mental Health Treatment
Emotional well-being is really significant for our general wellbeing and prosperity. Psychological well-being influences the manner in which we think, feel, act, and affects others in our lives also. Psychological well-being can be affected by the climate, hereditary qualities, and.
Read More